| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ALLHAT-LLT: Questions, questions, and more questions (and some answers)
|
Skerrett, Patrick J.
|
|
2004
|
|
5 |
p. 375-380
|
artikel
|
| 2 |
Apolipoprotein A-I and risk for cardiovascular diseases
|
Khuseyinova, Natalie
|
|
2006
|
|
5 |
p. 365-373
|
artikel
|
| 3 |
Are lower levels of low-density lipoprotein cholesterol beneficial? A review of recent data
|
Olsson, Anders G.
|
|
2006
|
|
5 |
p. 382-389
|
artikel
|
| 4 |
Are nuclear factors the ultimate targets of drugs affecting lipid metabolism?
|
Fruchart, Jean-Charles
|
|
2000
|
|
5 |
p. 353-354
|
artikel
|
| 5 |
ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients
|
Nambi, Vijay
|
|
2004
|
|
5 |
p. 353-358
|
artikel
|
| 6 |
Aspirin in the treatment and prevention of cardiovascular disease: Current perspectives and future directions
|
Hennekens, Charles H.
|
|
2007
|
|
5 |
p. 409-416
|
artikel
|
| 7 |
Atherosclerosis and diabetes: The rage connection
|
Schmidt, Ann Marie
|
|
2000
|
|
5 |
p. 430-436
|
artikel
|
| 8 |
Clinical insights into the diagnosis and management of atherosclerotic renal artery disease
|
Bloch, Michael J.
|
|
2006
|
|
5 |
p. 412-420
|
artikel
|
| 9 |
Clinical trials report
|
Toth, Peter P.
|
|
2005
|
|
5 |
p. 333-334
|
artikel
|
| 10 |
Clinical Trials Report
|
Toth, Peter P.
|
|
2006
|
|
5 |
p. 353-355
|
artikel
|
| 11 |
Clinical trials report
|
Toth, Peter P.
|
|
2004
|
|
5 |
p. 333-334
|
artikel
|
| 12 |
Clinical trials report
|
Hegele, Robert A.
|
|
2000
|
|
5 |
p. 361-362
|
artikel
|
| 13 |
Clinical trials report
|
Toth, Peter P.
|
|
2003
|
|
5 |
p. 339-340
|
artikel
|
| 14 |
Clopidogrel and risk for acute coronary events
|
Mood, Girish R.
|
|
2007
|
|
5 |
p. 401-408
|
artikel
|
| 15 |
Complex “Cross Talk” Involving Nitric Oxide Metabolites: Who’s Listening?
|
Hajjar, David P.
|
|
2006
|
|
5 |
p. 347-348
|
artikel
|
| 16 |
C-reactive protein and cardiovascular disease: Weighing the evidence
|
Lowe, Gordon D. O.
|
|
2006
|
|
5 |
p. 421-428
|
artikel
|
| 17 |
C-reactive protein and risk of cardiovascular disease: Evidence and clinical application
|
Ridker, Paul M.
|
|
2003
|
|
5 |
p. 341-349
|
artikel
|
| 18 |
Does it matter how you lower blood pressure in patients with uncomplicated hypertension? Weighing the evidence
|
Duprez, Daniel A.
|
|
2007
|
|
5 |
p. 352-358
|
artikel
|
| 19 |
Does it matter whether or not a lipid-lowering agent inhibits Rho kinase?
|
Liao, James K.
|
|
2007
|
|
5 |
p. 384-388
|
artikel
|
| 20 |
Dyslipidemia in South Asian patients
|
Enas, Enas A.
|
|
2007
|
|
5 |
p. 367-374
|
artikel
|
| 21 |
Evidence-based management of dyslipidemias in women
|
LaRosa, John C.
|
|
2003
|
|
5 |
p. 379-385
|
artikel
|
| 22 |
Evidence-based management of peripheral vascular disease
|
Shammas, Nicolas W.
|
|
2005
|
|
5 |
p. 358-363
|
artikel
|
| 23 |
Evidence-based treatment of lipids in the elderly
|
Eimer, Micah J.
|
|
2004
|
|
5 |
p. 388-397
|
artikel
|
| 24 |
Evidence-based treatment of unprotected left main disease: A critical review of the literature
|
Sharis, Peter
|
|
2007
|
|
5 |
p. 397-400
|
artikel
|
| 25 |
Extending the cardiovascular benefits of omega-3 fatty acids
|
Harris, William S.
|
|
2005
|
|
5 |
p. 375-380
|
artikel
|
| 26 |
Fibrate therapy in patients with metabolic syndrome and diabetes mellitus
|
Dayspring, Thomas
|
|
2006
|
|
5 |
p. 356-364
|
artikel
|
| 27 |
Gene therapy for myocardial angiogenesis: Has it come of age?
|
Kantor, Birgit
|
|
2000
|
|
5 |
p. 373-379
|
artikel
|
| 28 |
Genetics of atherosclerosis: The search for genes acting at the level of the vessel wall
|
Villa-Colinayo, Veronica
|
|
2000
|
|
5 |
p. 380-389
|
artikel
|
| 29 |
Hepatic high-density lipoprotein receptors: Roles in lipoprotein metabolism and potential for therapeutic modulation
|
Trigatti, Bernardo L.
|
|
2005
|
|
5 |
p. 344-350
|
artikel
|
| 30 |
Hepatic lipase: Friend or foe and under what circumstances?
|
Jansen, Hans
|
|
2004
|
|
5 |
p. 343-347
|
artikel
|
| 31 |
High-density lipoprotein: Is it always atheroprotective?
|
Ansell, Benjamin J.
|
|
2006
|
|
5 |
p. 405-411
|
artikel
|
| 32 |
High-density lipoprotein metabolism: Molecular targets for new therapies for atherosclerosis
|
Kawashiri, Masa-aki
|
|
2000
|
|
5 |
p. 363-372
|
artikel
|
| 33 |
High-density lipoprotein subfractions and risk of coronary artery disease
|
Morgan, John
|
|
2004
|
|
5 |
p. 359-365
|
artikel
|
| 34 |
Hypoadiponectinemia: A common basis for diseases associated with overnutrition
|
Funahashi, Tohru
|
|
2006
|
|
5 |
p. 433-438
|
artikel
|
| 35 |
Impact of thiazolidenediones on serum lipoprotein levels
|
Goldberg, Ronald B.
|
|
2006
|
|
5 |
p. 397-404
|
artikel
|
| 36 |
Impact of thiazolidinedione therapy on atherogenesis
|
Wijk, Jeroen P. H. van
|
|
2005
|
|
5 |
p. 369-374
|
artikel
|
| 37 |
Implications of the heart protection study for reducing coronary events in high-risk patients
|
Brown, William Virgil
|
|
2003
|
|
5 |
p. 358-363
|
artikel
|
| 38 |
Inhibition of cholesteryl ester transfer protein activity: A new therapeutic approach to raising high-density lipoprotein
|
Rader, Daniel J.
|
|
2004
|
|
5 |
p. 398-405
|
artikel
|
| 39 |
In-hospital initiation of statin therapy in patients with acute coronary events
|
Fonarow, Gregg C.
|
|
2003
|
|
5 |
p. 394-402
|
artikel
|
| 40 |
Insulin resistance in human partial lipodystrophy
|
Hegele, Robert A.
|
|
2000
|
|
5 |
p. 397-404
|
artikel
|
| 41 |
Isoprenoid metabolism and the pleiotropic effects of statins
|
Laufs, Ulrich
|
|
2003
|
|
5 |
p. 372-378
|
artikel
|
| 42 |
Lessons learned from the prospective pravastatin pooling project
|
Byington, Robert P.
|
|
2004
|
|
5 |
p. 366-374
|
artikel
|
| 43 |
Lipoprotein(a) and atherosclerosis: New perspectives on the mechanism of action of an enigmatic lipoprotein
|
Koschinsky, Marlys L.
|
|
2005
|
|
5 |
p. 389-395
|
artikel
|
| 44 |
Lipoprotein(a): Implications for clinical practice
|
Block, Robert C.
|
|
2005
|
|
5 |
p. 327-329
|
artikel
|
| 45 |
Lipoprotein-associated phospholipase A2: Pathogenic mechanisms and clinical utility for predicting cardiovascular events
|
Nambi, Vijay
|
|
2006
|
|
5 |
p. 374-381
|
artikel
|
| 46 |
Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk
|
Otarod, Jila Kaberi
|
|
2004
|
|
5 |
p. 335-342
|
artikel
|
| 47 |
Literature alert
|
Nasir, Khurram
|
|
2004
|
|
5 |
p. 328-329
|
artikel
|
| 48 |
Literature alert
|
|
|
2000
|
|
5 |
p. 356-358
|
artikel
|
| 49 |
Literature alert
|
|
|
2003
|
|
5 |
p. 334-335
|
artikel
|
| 50 |
Low-density lipoprotein particle number and risk for cardiovascular disease
|
Cromwell, William C.
|
|
2004
|
|
5 |
p. 381-387
|
artikel
|
| 51 |
Low-density lipoprotein reduction in high-risk patients: How low do you go?
|
Toth, Peter P.
|
|
2004
|
|
5 |
p. 348-352
|
artikel
|
| 52 |
Magnetic resonance imaging of coronary atherosclerosis
|
Fayad, Zahi A.
|
|
2003
|
|
5 |
p. 411-417
|
artikel
|
| 53 |
Metabolic syndrome: Demographic features, etiology, and clinical management
|
Wyne, Kathleen L.
|
|
2005
|
|
5 |
p. 381-388
|
artikel
|
| 54 |
Microalbuminuria and diabetic cardiovascular disease
|
MacIsaac, Richard J.
|
|
2003
|
|
5 |
p. 350-357
|
artikel
|
| 55 |
Mouse models of lipodystrophy
|
Reue, Karen
|
|
2000
|
|
5 |
p. 390-396
|
artikel
|
| 56 |
Myeloperoxidase and inflammatory proteins: Pathways for generating dysfunctional high-density lipoprotein in humans
|
Vaisar, Tomáš
|
|
2007
|
|
5 |
p. 417-424
|
artikel
|
| 57 |
New concepts in fibrinolysis and angiogenesis
|
Hajjar, Katherine A.
|
|
2000
|
|
5 |
p. 417-421
|
artikel
|
| 58 |
New concepts in vascular nitric oxide signaling
|
Oeckler, Richard A.
|
|
2000
|
|
5 |
p. 437-444
|
artikel
|
| 59 |
New insights in the treatment of dyslipidemia: A focus on cardiovascular event reduction and the antiatherosclerotic effects of atorvastatin
|
Toth, Peter P.
|
|
2005
|
|
5 |
p. 335-343
|
artikel
|
| 60 |
Niacin: A powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events
|
Davidson, Michael H.
|
|
2003
|
|
5 |
p. 418-422
|
artikel
|
| 61 |
Peroxisome proliferator activated receptors and stroke
|
Fruchart, Jean-Charles
|
|
2003
|
|
5 |
p. 331-332
|
artikel
|
| 62 |
Pleiotropic effects of fibrates
|
Chinetti-Gbaguidi, Giulia
|
|
2005
|
|
5 |
p. 396-401
|
artikel
|
| 63 |
Regulation of cell migration in atherosclerosis
|
Kraemer, Rosemary
|
|
2000
|
|
5 |
p. 445-452
|
artikel
|
| 64 |
Reverse cholesterol transport: High-density lipoprotein’s magnificent mile
|
Toth, Peter P.
|
|
2003
|
|
5 |
p. 386-393
|
artikel
|
| 65 |
Rimonabant: The role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients
|
Dibble, Christopher T.
|
|
2007
|
|
5 |
p. 359-366
|
artikel
|
| 66 |
Should hyperhomocysteinemia be treated in patients with atherosclerotic disease?
|
Maron, Bradley A.
|
|
2007
|
|
5 |
p. 375-383
|
artikel
|
| 67 |
SPARCL: The glimmer of statins for stroke risk reduction
|
Armani, Annemarie
|
|
2007
|
|
5 |
p. 347-351
|
artikel
|
| 68 |
Statin myopathy: Incidence, risk factors, and pathophysiology
|
Sewright, Kimberly A.
|
|
2007
|
|
5 |
p. 389-396
|
artikel
|
| 69 |
Statins and proteinuria
|
Vidt, Donald G.
|
|
2005
|
|
5 |
p. 351-357
|
artikel
|
| 70 |
Statins and the primary prevention of cardiovascular events
|
Clearfield, Michael
|
|
2006
|
|
5 |
p. 390-396
|
artikel
|
| 71 |
The CARDS trial: Diabetic patients dealt a winning hand
|
Armani, Annemarie
|
|
2006
|
|
5 |
p. 429-432
|
artikel
|
| 72 |
The COURAGE trial: Establishing the Therapeutic Legitimacy of Aggressive Risk Factor Management in Patients with Stable Coronary Artery Disease as an Alternative to Percutaneous Coronary Intervention
|
Toth, Peter P.
|
|
2007
|
|
5 |
p. 345-346
|
artikel
|
| 73 |
The good smooth muscle cells in atherosclerosis
|
Schwartz, Stephen M.
|
|
2000
|
|
5 |
p. 422-429
|
artikel
|
| 74 |
The insulin resistance syndrome
|
Reaven, Gerald M.
|
|
2003
|
|
5 |
p. 364-371
|
artikel
|
| 75 |
Therapeutic modulation of cellular cholesterol efflux
|
Wang, Nan
|
|
2001
|
|
5 |
p. 345-347
|
artikel
|
| 76 |
The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: Insights from genetic studies
|
Luttun, Aernout
|
|
2000
|
|
5 |
p. 407-416
|
artikel
|
| 77 |
The role of statins in the prevention of ischemic stroke
|
Ziedén, Bo
|
|
2005
|
|
5 |
p. 364-368
|
artikel
|
| 78 |
Toxicity of antilipidemic agents: Facts and fictions
|
Xydakis, Antonios M.
|
|
2003
|
|
5 |
p. 403-410
|
artikel
|
| 79 |
Web alert
|
|
|
2007
|
|
5 |
p. 341
|
artikel
|
| 80 |
Web alert
|
|
|
2000
|
|
5 |
p. 453
|
artikel
|
| 81 |
Web alert
|
|
|
2003
|
|
5 |
p. 423
|
artikel
|
| 82 |
Web alert
|
|
|
2005
|
|
5 |
p. 330
|
artikel
|
| 83 |
Web alert
|
|
|
2004
|
|
5 |
p. 330
|
artikel
|
| 84 |
Web alert
|
Chilton, Robert
|
|
2006
|
|
5 |
p. 349
|
artikel
|
Tijdschrift beschrijving